[Pharmacological properties of mono- and bisquanylhydrazones].
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002415:Cats; D004352:Drug Resistance, Microbial; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000188:drug therapy; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D014345:Trypanosoma / Q000187:drug effects; D014352:Trypanosomiasis / Q000188:drug therapy
D000970:Antineoplastic Agents; D006571:Heterocyclic Compounds
Pharmakologische Eigenschaften von Mono- und Bisguanylhydrazonen.